Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Parasitic fish could lead to more effective treatments for brain disease
Molecules from sea lampreys could be combined with other therapies to deliver drugs directly to the human brain.

Researchers assess the effectiveness of sea lamprey molecules on glioblastoma

A parasitic fish renowned for its distinctive, disc-shaped mouth could pave the way to more effective treatments for brain conditions, including cancer and stroke.
 
Native to the Northern Hemisphere, the sea lamprey is an ancient species of fish that closely resembles an eel. Its mouth is filled with sharp, hook-shaped teeth, that it uses to feed off other fish.

Now, new research suggests that molecules from sea lampreys could be combined with other therapies to deliver drugs directly to the human brain.

The study, led by the universities of Wisconsin-Madison and Texas, looked at a set of molecules from the lamprey’s immune system called VLRs (variable lymphocyte receptors). While most medicines target specific features on or inside an individual’s cells, VLRs are different because they target the extracellular matrix (ECM) - a mesh of proteins and sugars that both surround and support brain cells.

Researchers believe these molecules could be adapted and combined with an array of other therapies, giving hope to people with brain tumours, multiple sclerosis, Alzheimer’s disease or even traumatic head injuries.

“This set of targeting molecules appears somewhat agnostic to the disease,” says Eric Shusta, a professor of chemical and biological engineering at UW–Madison. “We believe it could be applied as a platform technology across multiple conditions.”

The technology takes advantage that many diseases disrupt the blood-brain barrier. This is what lines the blood vessels of the central nervous system and protects the brain from toxins and pathogens.
In some illnesses, this blood-brain barrier leaks around the disease area, offering a unique entry point for any treatment.

In the study, researchers assessed the effectiveness of VLRs in mouse models of glioblastoma, an incurable brain cancer. The team bound the VLRs to an approved chemotherapy drug called doxorubicin and found that the treatment prolonged the rodents’ survival.

The team note that it’s possible that drugs delivered to the matrix could accumulate to a much higher therapeutic dose than medicines aimed at the inside of cells.

Collaborator John Kuo, a neurosurgeon-scientist and professor of neurosurgery at the University of Texas at Austin, said: “Similar to water soaking into a sponge, the lamprey molecules will potentially accumulate much more of the drug in the abundant matrix around cells compared to specific delivery to cells.”

The team are now planning to link the VLR molecules to additional anti-cancer drugs, such as immunotherapy agents that activate a patient’s own immune system to destroy tumours. They also see promise in using the molecules as diagnostic tools to detect blood-brain barrier disruption.

“I’m excited about trying this strategy in different disease model systems,” says Kuo. “There are several disease processes that disrupt the blood-brain barrier and we could conceive of delivering a variety of different therapies with these molecules.”

The study, Identification of variable lymphocyte receptors that can target therapeutics to pathologically exposed brain extracellular matrix, is published in the journal Science Advances.

Image (C) NOAA Great Lakes Environmental

Become a member or log in to add this story to your CPD history

Vets to run marathon for World Animal Protection

News Story 1
 Two recently graduated veterinary surgeons will be running the London Marathon in April to raise money for the charity World Animal Protection.

Alex Bartlett and Maeve O'Neill plan to run the race together if they are given the same start times.

Dr O'Neill said: "You're always limited in what you can do to help animals, so it is nice to raise money for a charity that helps animals around the world."

Dr Bartlett added: "I have never run a marathon before and am excited to run my first one for such a good cause!"

Both Dr Bartlett and Dr O'Neill have fundraising pages online. 

Click here for more...
News Shorts
BSAVA releases new Guide to Procedures

The British Small Animal Veterinary Association (BSAVA) has published a new edition of its Guide to Procedures for Small Animal Practice.

It has added four new procedures; cystostomy tube placement, endotracheal intubation, point-of-care ultrasound and wet-to-dry dressings.

BSAVA says that it is an essential step-by-step guide to diagnostic and therapeutic procedures performed in practice. The textbook includes new images and illustrations, as well as high-definition videos for use prior to procedures.

Nick Bexfield and Julia Riggs, editors of the new edition, said: "We have built upon the success of the previous editions by responding to the feedback received from the BSAVA readership, and hope this new guide helps to further increase the confidence and accuracy with which these procedures are performed."

Print copies are available in the BSAVA store, with a digital version in the BSAVA library.